Okay, here’s a breakdown of the provided text, summarizing the key findings of the study:
Study Focus:
This study investigates double seronegative Myasthenia Gravis (dSNMG) – a form of the autoimmune disorder Myasthenia Gravis (MG) where standard antibody tests are negative. The researchers aimed to gather data from case reports and series to better understand this less common presentation of MG.
Methods:
* literature Search: PubMed and Google Scholar were searched for English-language articles published up to October 31, 2022.
* Inclusion Criteria: Case reports and series with extractable data on dSNMG were included.
* Exclusion Criteria: Articles not in English, unclear MG diagnoses, cases without proof of seronegative MG, cases with other neuromuscular disorders, and reports lacking MG confirmation were excluded.
Key Findings:
* Number of cases: The study included 40 articles, detailing 35 individual case reports and 5 small case series, encompassing a total of 45 patients with dSNMG.
* Demographics:
* Mean age at diagnosis: 52.4 years
* Mean age of symptom onset: 50.7 years
* More women were affected (51.1%).
* clinical Presentation:
* Generalized MG (affecting multiple muscle groups) was present in 71.1% of patients.
* Isolated ocular MG (affecting only the eyes) was present in 28.8% of patients.
* Ocular symptoms were the most common symptom (82.2%), followed by limb weakness (53.3%) and dysphagia (difficulty swallowing - 26.6%).
* 17.7% of patients experienced a myasthenic crisis (a severe worsening of MG symptoms).
* Malignancy Association:
* Patients with co-existing malignancy (cancer) were older (mean age 68.5 years) than those without (mean age 48.6 years).
* patients with malignancy had worse treatment outcomes (37.5% favorable outcome) compared to those without malignancy (78.6% favorable outcome).
* LRP4 and Ocular MG: Ther was a trend towards ocular MG being more common in patients who were LRP4-positive, but this difference was not statistically meaningful.
* Treatment Outcomes: There were no significant differences in treatment outcomes across the 3 treatment groups.
In essence, the study provides a descriptive overview of dSNMG, highlighting its typical age of onset, gender distribution, common symptoms, and a potential association with malignancy and poorer outcomes.
